XOMA (NASDAQ:XOMA) Posts Quarterly Earnings Results, Misses Estimates By $0.17 EPS

XOMA (NASDAQ:XOMA) issued its earnings results on Monday. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17), Zacks reports. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%.

XOMA Stock Performance

XOMA stock traded up $0.29 during midday trading on Monday, reaching $20.73. 20,213 shares of the company were exchanged, compared to its average volume of 26,083. XOMA has a one year low of $19.92 and a one year high of $35.00. The firm has a market capitalization of $244.26 million, a price-to-earnings ratio of -5.96 and a beta of 1.00. The business has a 50-day moving average price of $24.85 and a two-hundred day moving average price of $27.41. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

Insider Activity

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 7.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on XOMA. HC Wainwright lowered their price objective on shares of XOMA from $123.00 to $104.00 and set a “buy” rating on the stock in a research note on Monday, February 3rd. StockNews.com downgraded XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.